Pfizer to cease operation at two plants in Maharashtra & Tamil Nadu
Category: #health  By Ojaswita Kutepatil  Date: 2019-01-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer to cease operation at two plants in Maharashtra & Tamil Nadu

In what may seem to be a response against failing product demand, the U.S. drug manufacturer Pfizer announced that it will be closing its two manufacturing plants in India. The plants, reportedly, manufactured generic injectable such as the penicillin.

According to sources familiar with the matter, the closure of the two plants situated in the states of Maharashtra and Tamil Nadu will affect the employment scenario of more than 1,700 people. These two factories, for the record, employs roughly 6% of Pfizer’s global employees.

Pfizer said that it has conducted a thorough research of the sites and has evaluated that the factories has been incurring significant long-term losses in terms of product demand, and concluded that manufacturing at these sits will not be financially viable for the company.

Reportedly, the U.S. based pharma major acquired the factories in 2015 as a part of its USD 15 billion purchase of Hospira. It aimed to boost the company’s current portfolio of generic injectable drugs & copies of biotech related medicines

As reported by Reuters, Pfizer is also shutting down a Hospira R&D lab located in Taramani, Chennai, however, the closing of this lab was not related to the two manufacturing plants. A spokesperson further revealed that nearly 150 employees were reported of the shutdown, in the fourth quarter.

Sources cite that Pfizer’s Chennai-based manufacturing plant manufactured generic injectable penicillin, penems, and cephalosporin, while the Aurangabad-based unit supplied the Chennai plant with specific products. It has been reported that both the plants in India did not manufacture products for the domestic market.

According reliable reports, the Aurangabad site currently employs over 700 people, while the Chennai unit employs around 1000 people.

Pfizer, however said that the exact time of the exit is not yet be planned and further revealed that it will be expanding operations in its Visakhapatnam-based facility that will cater to export markets including U.S. as well as Canada.



About Author

Ojaswita Kutepatil

Email: [email protected]   

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, presently develops content for Market Size Forecasters, Algosonline, and other similar platforms. Having had a prior experience in Business Development and Technical Engineering, she now pens down articles pe...

Read More

More News By Ojaswita Kutepatil

Pepperfry to pump $12M in expansion & boost supply chain operations
Pepperfry to pump $12M in expansion & boost supply chain operations
By Ojaswita Kutepatil

The Mumbai-based online retailer also looks to step into areas like augmented/virtual reality to advance shopping experience.

Pepperfry, the online furniture & ...

Dream Incubator leads health-tech firm NIRAMAI’s Series A funding
Dream Incubator leads health-tech firm NIRAMAI’s Series A funding
By Ojaswita Kutepatil

NIRAMAI Health Analytix Pvt. Ltd., the Bengaluru-based breast cancer screening start-up, has reportedly raised around $6 million in Series A investment round that was led by Dream Incubator, a management consulting fir...

Levi Strauss plans share market comeback after more than 3 decades
Levi Strauss plans share market comeback after more than 3 decades
By Ojaswita Kutepatil

In a recent turn of events, renowned Jeans manufacturer Levi Strauss & Co has reportedly filed documents for getting listed on the New York Stock Exchange, on the lookout for returning to public markets after over ...